Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6901550 | 1.00 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL30176889 | 0.87 | MAPT (0.42) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL27758538 | 0.84 | MAPT (0.40) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL8996550 | 0.81 | MAPT (0.55) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL27522285 | 0.80 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL6043241 | 0.79 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL7158785 | 0.79 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL31180746 | 0.79 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL6831561 | 0.79 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL924280 | 0.79 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981916-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981916-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981916-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3066082-B1 | 5,6,7,8-TETRAHYDRO-5,8-METHANOCINNOLINE DERIVATIVES AS RORC MODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-3066082-B1 | 5,6,7,8-TETRAHYDRO-5,8-METHANOCINNOLINE DERIVATIVES AS RORC MODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-20150126491-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126491-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126491-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | EPHX2 2855/4885MAPT 2112/4885MAPK1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.